PROFARM PS Selects QAD Enterprise Applications to Meet Compliance Needs
09 September 2010 - 10:00PM
Business Wire
QAD Inc. (NASDAQ: QADI), a leading provider of enterprise
software and services for global manufacturers, announced today
that PROFARM PS, a fast growing pharmaceuticals distributor based
in Poland, has extended its commitment to QAD by upgrading to QAD
Enterprise Applications. QAD expects to complete the implementation
rapidly and for the PROFARM system to go live by year-end 2010.
PROFARM, whose business is focused on growth from the vaccine
market, needed a solution to address regulatory compliance issues
of the pharmaceutical industry and provide validation of its IT
systems to current good manufacturing practices (cGMP).
With a 13-year history with QAD, PROFARM elected to upgrade to
QAD Enterprise Applications for its improved capabilities and
performance. “We are committed to QAD because we are pleased with
our long-term relationship,” explained Piotr Steczniewski, deputy
CEO at PROFARM PS. “In addition, QAD understands how important
transferring our data safely and efficiently is to our
business.”
QAD has a strong foothold in the pharmaceutical market and
understands the regulatory pressures and stringent requirements
that its customers face, particularly the need to maintain secure
and auditable systems.
”With QAD Enterprise Applications, PROFARM is equipped with the
right tools to manage validation, electronic batch records and
electronic signatures, comprehensive audit trails and other
traceability issues, while reducing risk and cost-effectively
managing its compliance initiatives,” said Jean-Claude Walravens,
QAD senior vice president EMEA.
PROFARM was particularly impressed by QAD Enterprise
Applications process maps, as they are designed specifically for
the pharmaceutical market.
Overall, the implementation also will provide stock management,
finance, accounting, and transport planning support, a function
that, until recently, was prepared outside of the main system.
“We are very excited about this implementation. Our last IT
system has been in service for many years and validation has proved
demanding,” explained Steczniewski. “We believe with this upgrade,
QAD will help us simplify the validation process and provide the
overall functionality we need to grow.”
Join QAD on: Facebook, Twitter, LinkedIn, YouTube
About PROFARM PS
PROFARM PS Sp. z.o.o. is a leading distributor providing health
products and supplies from pharmaceutical companies including Astra
Zeneca, MSD, Abbott, Pfizer, Baxter and Ipsen International to
hospitals and medical wholesalers. Established in 1989 and
headquartered in Warsaw, Poland, PROFARM PS is one of the first
private pharmaceutical companies in Poland.
About QAD
QAD is a leading provider of enterprise applications for global
manufacturing companies specializing in automotive, consumer
products, electronics, food and beverage, industrial and life
science products. QAD applications provide critical functionality
for managing manufacturing resources and operations within and
beyond the enterprise, enabling global manufacturers to collaborate
with their customers, suppliers and partners to make and deliver
the right product, at the right cost and at the right time. For
more information about QAD, telephone +1 805-566-6000, or visit the
QAD web site at www.qad.com.
"QAD" is a registered trademark of QAD Inc. All other products
or company names herein may be trademarks of their respective
owners.
Note to Investors:
This press release contains certain
forward-looking statements made under the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. A number
of risks and uncertainties could cause actual results to differ
materially from those in the forward-looking statements. These
risks include, but are not limited to, evolving demand for the
company's software products and products that operate with the
company's products; the company's ability to sustain license and
service demand; the company's ability to leverage changes in
technology; the company's ability to sustain customer renewal rates
at current levels; the publication of opinions by industry and
financial analysts about the company, its products and technology;
the reliability of estimates of transaction and integration costs
and benefits; the entry of new competitors or new offerings by
existing competitors and the associated announcement of new
products and technological advances by them; delays in localizing
the company's products for new or existing markets; the ability to
recruit and retain key personnel; delays in sales as a result of
lengthy sales cycles; changes in operating expenses, pricing,
timing of new product releases, the method of product distribution
or product mix; timely and effective integration of newly acquired
businesses; general economic conditions; exchange rate
fluctuations; and, the global political environment. In addition,
revenue and earnings in the enterprise resource planning (ERP)
software industry are subject to fluctuations. Software license
revenue, in particular, is subject to variability with a
significant proportion of revenue earned in the last month of each
quarter. Given the high margins associated with license revenue,
modest fluctuations can have a substantial impact on net income.
Investors should not use any one quarter's results as a benchmark
for future performance. For a more detailed description of the risk
factors associated with the company and the industries in which it
operates, please refer to the company's Annual Report on Form 10-K
for fiscal 2010 ended January 31, 2010.
Qad Inc. (MM) (NASDAQ:QADI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qad Inc. (MM) (NASDAQ:QADI)
Historical Stock Chart
From Jul 2023 to Jul 2024